PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...

Diabetic kidney disease (DKD) progression is not well understood. Using high-throughput proteomics, biostatistical, pathway and machine learning tools, we examine the urinary Complement proteome in ...

The MarketWatch News Department was not involved in the creation of this content. -- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...